The global cell culture market reached USD 29.51 billion in 2025 and is set to grow at a compound annual rate of 11% through 2034, when Contrive Datum Insights projects revenue of USD 73.8 billion, up from USD 32.02 billion in 2026.
The market covers the consumables and equipment that support growing cells outside their natural environment under controlled laboratory or manufacturing conditions. Buyers include biopharmaceutical and biotechnology manufacturers producing therapeutic proteins and vaccines, academic and research institutes, and contract research and development organizations serving external sponsors. On the consumables side this includes growth media, serum, and specialty reagents needed at every passage; on the equipment side, incubators, biosafety cabinets, and culture systems used to grow and maintain cells.
Expansion of monoclonal antibody and recombinant protein manufacturing capacity carries the highest rated impact on growth over the forecast period. Its clearest effect shows up in F-10 Serum Free Media, a consumable line compounding at 15.14% a year, well above the market's 11%. That line's share of revenue climbs from 6.43% in 2025 to 9% by 2034, and its value rises from USD 1.9 billion to USD 6.64 billion.
Segment data show a similar split between scale and speed. By product, Culture Systems led 2025 revenue with 32% of the total, worth USD 9.44 billion, while Cryostorage Equipment grows fastest at 17.83%. By application, Biopharmaceuticals accounted for 34% of 2025 revenue at USD 10.03 billion, while Gene Therapy is the fastest-growing application at 18.7%. Pharmaceutical and biotechnology companies are the largest end users, holding 48% of 2025 revenue at USD 14.16 billion, while Contract Research Organizations and CDMOs grow fastest among end users at 14.54%. Mammalian cell culture dominates by cell type with 88% of 2025 revenue (USD 25.97 billion); non-mammalian cell culture grows faster, at 12.92%.
By consumable, Fetal Bovine Serum is the single largest line, holding 19.86% of 2025 revenue at USD 5.86 billion and still accounting for 16% of the total by 2034; its own growth rate of 8.35% trails the market average.
North America generated 36.21% of 2025 revenue (USD 10.69 billion) and is projected to reach USD 24.35 billion by 2034; the United States alone accounts for USD 9.09 billion of 2025 revenue, 30.8% of the global total. Asia Pacific's share rises over the same period, from 26.86% in 2025 to 32% in 2034, with revenue growing from USD 7.93 billion to USD 23.62 billion. Middle East and Africa stays the smallest region throughout, holding 5% of revenue in both 2025 and 2034.
The USD 73.8 billion base-case figure for 2034 sits between two bounds the study also models. A bull case, in which biologics and cell and gene therapy manufacturing capacity expansions stay on their announced timelines and serum-free media adoption accelerates beyond the base case, puts 2034 revenue at USD 79.7 billion. A bear case, built on slower cell and gene therapy commercialisation together with continued volatility in fetal bovine serum supply and price, holds 2034 revenue to USD 67.9 billion instead. Since Fetal Bovine Serum alone carries close to a fifth of current revenue, sustained disruption to that single input is enough to move the market off its base-case path.
The full report segments the market across five axes, consumable, product, application, end user, and cell type, with revenue and growth rates for every line from 2020 through 2034, plus country-level detail across all five regions, competitive landscape, and methodology. It is delivered as a PDF, with a free sample available on request.